EN
SINOVAC Honored "MITRA BUMN GLOBAL CHAMPION 2022" for its success collaborating with Indonesia's SOEs to supply the COVID-19 vaccine
May 9, 2022 – Jakarta, Indonesia – SINOVAC Biotech Ltd., (SINOVAC), a leading provider of biopharmaceutical products in China, has been honored with the "MITRA BUMN GLOBAL CHAMPION 2022" award from the Indonesia State Ministry for State-Owned Enterprises (SOE). The award recognizes SINOVAC's contributions while serving as a partner to Indonesia's SOEs and success helping Indonesia produce and supply the COVID-19 vaccine during the pandemic.
SINOVAC Country Head of Indonesia received the award
SINOVAC, the only biopharmaceutical company to be awarded, has provided Indonesia with more than 280 million doses of its CoronaVac® COVID-19 vaccine. Of these, more than 100 million doses were delivered in semi-manufactured form, and filled and packaged by the Indonesian SOE, Bio Farma, to supply the Indonesia government's immunization programs.
The Indonesia State Ministry for SOEs delivered the award during an award ceremony, held today with the aim of strengthening synergy between Indonesia's SOEs and the private sector to encourage national economic development.
"The synergy between the lines, both from SOEs and private sectors is very important in building the nation's independence," said Erick Thohir, minister of SOEs. "Especially amid an era of uncertainty due to the pandemic, which disrupted the supply chain."
To ensure the national supply of COVID-19 vaccine in Indonesia, SINOVAC and Bio Farma reached a joint production agreement on Aug. 20, 2021, making SINOVAC the first company to cooperate with the SOE. In January 2021, the SINOVAC CoronaVac® COVID-19 vaccine was the first to be approved by the Indonesian government for emergency use and halal certification. On Jan. 13, 2021, Joko Widodo, president of Indonesia, became the first person in Indonesia to be vaccinated. With his first dose of CoronaVac®, he kicked off the nation's mass public vaccination.
In February 2021, Indonesia approved CoronaVac® for the elderly and in November 2021 it was approved for children aged 6 to 11, the only vaccine approved for use in this age group.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company’s website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com